



Targeted Therapy for Bladder Cancer

Guest Editor:

Prof. Maximilian Burger

Department of Urology, Caritas-
St. Josef Medical Center,
University of Regensburg,
Germany

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editor

Dear Colleagues,

This Special Issue is titled: “Targeted Therapy for bladder cancer” Why bladder cancer and why targeted therapy, though? Uro-oncology has improved massively over the past few years; surgery for localized disease has improved, and so has systemic medical therapy for metastatic disease. We have understood the great potential of local therapy in metastatic disease and the combination of local and systemic therapy in locally advanced disease; some old paradigms seem to have been overcome, too. These statements, however, are justified in prostate and renal cell cancer more than in bladder cancer, where many unmet yet clinically pressing needs remain to be tackled: Can we expand bladder preservation in high-risk non-muscle-invasive stages? Thus, unmet needs and targeted therapy may meet in bladder cancer. This Special Issue aims at original work and overviews adding to the current knowledge and showing potential future approaches of surgical and medical therapy aiming at predefined targets in non- and muscle-invasive, and locally advanced and metastatic stages.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)